ALNY vs MRNA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ALNY Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alnylam Pharmaceuticals, Inc. (ALNY) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, ALNY trades at 14.5x Forward P/E with 19.5% operating margin (+16.7% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, ALNY sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ALNY Revenue | MRNA Revenue | ALNY Op. Margin | MRNA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $70M | $140M | -1087.6% | -306.0% | MRNA |
| FY2019 | $220M | $60M | -427.5% | -906.8% | ALNY |
| FY2020 | $490M | $800M | -168.1% | -95.0% | MRNA |
| FY2021 | $840M | $18.5B | -83.9% | 72.0% | MRNA |
| FY2022 | $1.04B | $19.3B | -75.7% | 48.9% | MRNA |
| FY2023 | $1.83B | $6.85B | -15.4% | -61.9% | ALNY |
| FY2024 | $2.25B | $3.24B | -7.9% | -121.9% | ALNY |
| FY2025 | $3.71B | $1.94B | 13.5% | -158.1% | ALNY |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ALNY | MRNA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $19.8B | $80.7B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | 7.5x | 23.0x | Lower Multiple | ALNY |
| Forward P/E Ratio Valuation | 14.5x | 23.0x | Lower Multiple | ALNY |
| Revenue Growth (YoY) Growth | +16.7% | +29.2% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | 19.5% | -80.8% | Higher Margin | ALNY |
| Net Profit Margin Profitability | 52.8% | -110.5% | Higher Margin | ALNY |
| Return on Equity (ROE) Capital Efficiency | 138.1% | -34.5% | Higher ROE | ALNY |
| 52-Week Range Position Momentum | 0% ($143โ$477) | 67% ($22โ$281) | Stronger Trend | MRNA |
| Beta / 30D Volatility Risk Regime | 0.54ฮฒ ยท 94% Vol | 2.23ฮฒ ยท 78% Vol | Lower Realized Risk | MRNA |
| Unified Institutional Score Composite Signal | 48.8 / 100 (HOLD) | 40.3 / 100 (SELL) | Higher Composite | ALNY |